Form 4: Cogent Biosciences Director Acquires Stock Options
SEC Form 4 Filing
Karen Jean Ferrante, a director of Cogent Biosciences, acquired 44,700 stock options on June 5, 2024.
Summary
- On June 5, 2024, Karen Jean Ferrante, a director of Cogent Biosciences, acquired 44,700 stock options.
- The exercise price of these options is $8.92.
- The options vest in full upon the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting of Stockholders.
- Following the transaction, Ferrante beneficially owns 44,700 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting a standard stock option grant to a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. It's a routine part of corporate governance and transparency.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to potential dilution upon exercise of the options.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: Director acquired stock options |
| 06/05/2024 | Stock option grant date |
| 06/05/2034 | Stock option expiration date |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.